Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Impact of SARS-CoV-2 infection on patients with systemic lupus erythematosus in England prior to vaccination: a retrospective observational cohort study

Rabe et al., BMJ Open, doi:10.1136/bmjopen-2022-071072
Nov 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Case 29% Improvement Relative Risk HCQ for COVID-19  Rabe et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 6,145 patients in the United Kingdom (May - Oct 2020) Fewer cases with HCQ (not stat. sig., p=0.22) c19hcq.org Rabe et al., BMJ Open, November 2023 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
Retrospective cohort of 6,145 SLE patients showing lower incidence of COVID-19 for patients receiving HCQ/CQ (antimalarials), without statistical significance. Groups were not matched and results may be influenced by factors such as disease severity. HCQ/antimalarials were used more in moderate/severe SLE patients, suggesting that the estimated protective effect will underestimate the real effect.
Although the 29% fewer cases is not statistically significant, it is consistent with the significant 28% fewer cases [20‑35%] from meta analysis of the 81 cases results to date.
risk of case, 28.6% lower, RR 0.71, p = 0.22, treatment 24 of 3,248 (0.7%), control 30 of 2,897 (1.0%), NNT 337.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rabe et al., 22 Nov 2023, retrospective, United Kingdom, peer-reviewed, mean age 45.2, 7 authors, study period 1 May, 2020 - 31 October, 2020.
This PaperHCQAll
Impact of SARS-CoV-2 infection on patients with systemic lupus erythematosus in England prior to vaccination: a retrospective observational cohort study
Adrian Paul J Rabe, Wei Jie Loke, Rubana N Kalyani, Raj Tummala, Heide A Stirnadel-Farrant, John Were, Kevin L Winthrop
BMJ Open, doi:10.1136/bmjopen-2022-071072
Objectives Determine the prevaccination healthcare impact of COVID-19 in patients with systemic lupus erythematosus (SLE) in England. Design Retrospective cohort study of adult patients with SLE from 1 May to 31 October 2020. Setting Clinical Practice Research Datalink (CPRD) Aurum and Hospital Episode Statistics (HES) databases from general practitioners across England combining primary care and other health-related data. Participants Overall, 6145 adults with confirmed SLE diagnosis ≥1 year prior to 1 May 2020 were included. Most patients were women (91.0%), white (67.1%), and diagnosed with SLE at age <50 (70.8%). Patients were excluded if they had a COVID-19 diagnosis before 1 May 2020. Primary and secondary outcome measures Demographics and clinical characteristics were compared. COVID-19 severity was determined by patient care required and procedure/diagnosis codes. COVID-19 cumulative incidence, hospitalisation rates, lengths of stay and mortality rates were determined and stratified by SLE and COVID-19 severity. Results Of 6145 patients, 3927 had mild, 1288 moderate and 930 severe SLE at baseline. The majority of patients with moderate to severe SLE were on oral corticosteroids and antimalarial treatments. Overall, 54/6145 (0.88%) patients with SLE acquired and were diagnosed with COVID-19, with 45 classified as mild, 6 moderate and 3 severe COVID-19. Cumulative incidence was higher in patients with severe SLE (1.4%) compared with patients classified as mild (0.8%) or moderate (0.8%). Ten COVID-19-specific hospital admissions occurred (n=6 moderate; n=4 severe). Regardless of COVID-19 status, hospital admission rates and length of stay increased with SLE severity. Of 54 patients with SLE diagnosed with COVID-19, 1 (1.9%) COVID-19-related death was recorded in a patient with both severe SLE and severe COVID-19. Conclusions SLE severity did not appear to impact COVID-19 outcomes in this study. The COVID-19 pandemic is evolving and follow-up studies are needed to understand the relationship between COVID-19 and SLE. ⇒ This study provided unique insight into the outcomes of COVID-19 for patients with systemic lupus erythematosus (SLE) before the availability of COVID-19 vaccines. ⇒ Due to the nature of a database study, there were limitations in the data captured in the system. ⇒ The number of diagnosed COVID-19 cases was low in patients with SLE. ⇒ The information about secondary care prescriptions in this population was limited.
Ethics approval This study used data that existed in an anonymised, structured format that contained no personal patient information. The study protocol was reviewed and approved by CPRD's Independent Scientific Advisory Committee (application number 21_000327) on 9 March 2021. Linkage of datasets was performed using anonymised and pseudonymised patient identification codes and was undertaken by NHS Digital, following study protocol approval. The CPRD obtains research ethics approval annually for receiving and supplying patient data for public health research from the UK's Health Research Authority Research Ethics Committee; no additional ethics approval is required for observational studies in public health research using CPRD Aurum data. Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available upon reasonable request. Data underlying the findings described in this article may be obtained in accordance with AstraZeneca's data sharing policy described at https://astrazenecagrouptrials. pharmacm.com/ST/Submission/Disclosure Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any..
References
Azkur, Akdis, Azkur, Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19, Allergy, doi:10.1111/all.14364
Ballow, Haga, Why do some people develop serious COVID-19 disease after infection, while others only exhibit mild symptoms?, J Allergy Clin Immunol Pract, doi:10.1016/j.jaip.2021.01.012
Bruce, 'keeffe, Farewell, Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, Ann Rheum Dis, doi:10.1136/annrheumdis-2013-205171
Castro, Gurzenda, Macário, Characteristics, outcomes and risk factors for mortality of 522 167 patients hospitalised with COVID-19 in Brazil: a retrospective cohort study, BMJ Open, doi:10.1136/bmjopen-2021-049089
Choi, Smith, SARS-CoV-2 variants of concern, Yonsei Med J, doi:10.3349/ymj.2021.62.11.961
Fanouriakis, Kostopoulou, Alunno, Update of the EULAR recommendations for the management of systemic lupus erythematosus, Ann Rheum Dis, doi:10.1136/annrheumdis-2019-215089
Felten, Kawka, Dubois, Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study, Lancet Rheumatol, doi:10.1016/S2665-9913(21)00221-6
Fernandez-Ruiz, Paredes, Niewold, COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease, Transl Res, doi:10.1016/j.trsl.2020.12.007
Gallagher, Dedman, Padmanabhan, The accuracy of date of death recording in the clinical practice research datalink GOLD database in England compared with the office for national statistics death registrations, Pharmacoepidemiol Drug Saf, doi:10.1002/pds.4747
Garris, Jhingran, Bass, Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan, J Med Econ, doi:10.3111/13696998.2013.778270
Gov, Uk, Coronavirus (COVID-19): guidance
Harshfield, Abel, Barclay, Do GPs accurately record date of death? A UK observational analysis, BMJ Support Palliat Care, doi:10.1136/bmjspcare-2018-001514
Harvey, Carabelli, Jackson, SARS-CoV-2 variants, spike mutations and immune escape, Nat Rev Microbiol, doi:10.1038/s41579-021-00573-0
Hasan, Haider, Stigler, The global case-fatality rate of COVID-19 has been declining since may 2020, Am J Trop Med Hyg, doi:10.4269/ajtmh.20-1496
Jordan, Adab, Cheng, Covid-19: risk factors for severe disease and death, BMJ, doi:10.1136/bmj.m1198
Katsuyama, Tsokos, Moulton, Aberrant T cell signaling and subsets in systemic lupus erythematosus, Front Immunol, doi:10.3389/fimmu.2018.01088
Ko, Koelmeyer, Li, Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis, Semin Arthritis Rheum, doi:10.1016/j.semarthrit.2022.152099
Langham, Barut, Samnaliev, Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: a real-world observational retrospective cohort analysis, Rheumatol Adv Pract, doi:10.1093/rap/rkab061
Li, Wu, Nie, The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity, Cell, doi:10.1016/j.cell.2020.07.012
Liu, Davidson, Taming lupus-a new understanding of pathogenesis is leading to clinical advances, Nat Med, doi:10.1038/nm.2752
Lupus Uk, Lupus & Coronavirus (COVID-19
Majeed, Pollock, Hodes, Implementation of COVID-19 vaccination in the United Kingdom, BMJ, doi:10.1136/bmj-2022-070344
Martindale, Pilbeam, Mableson, Perspectives on COVID-19 testing policies and practices: a qualitative study with scientific advisors and NHS health care workers in England, BMC Public Health, doi:10.1186/s12889-021-11285-8
Mehta, Gasparyan, Zimba, Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management, Clin Rheumatol, doi:10.1007/s10067-022-06227-7
Morawski, Bolland, Expanding the B cell-centric view of systemic lupus erythematosus, Trends Immunol, doi:10.1016/j.it.2017.02.001
Murphy, Scott, Salisbury, Implementation of remote consulting in UK primary care following the COVID-19 pandemic: a mixed-methods longitudinal study, Br J Gen Pract, doi:10.3399/BJGP.2020.0948
Nhs, Healthcare associated COVID-19 infections -further action
Nhs, NHS offers COVID jab to clinically vulnerable and people 65 to 69
Nhs, Shielded patient list
Nune, Iyengar, Ahmed, Impact of COVID-19 on rheumatology practice in the UK-a pan-regional rheumatology survey, Clin Rheumatol, doi:10.1007/s10067-021-05601-1
Park, Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19), Clin Exp Pediatr, doi:10.3345/cep.2020.00493
Ramirez, Gerosa, Beretta, COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients, Semin Arthritis Rheum, doi:10.1016/j.semarthrit.2020.06.012
Rees, Doherty, Grainge, The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012, Ann Rheum Dis, doi:10.1136/annrheumdis-2014-206334
Sawah, Zhang, Zhu, Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort, Lupus Sci Med, doi:10.1136/lupus-2014-000066
Saxena, Engel, Banbury, Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City, Lancet Rheumatol, doi:10.1016/S2665-9913(22)00190-4
Sheane, Gladman, Su, Disease outcomes in glucocorticosteroid-naive patients with systemic lupus erythematosus, Arthritis Care Res, doi:10.1002/acr.22938
Speyer, Li, Guan, Comparison of an administrative algorithm for SLE disease severity to clinical SLE disease activity index scores, Rheumatol Int, doi:10.1007/s00296-019-04477-4
Toyoshima, Nemoto, Matsumoto, SARS-CoV-2 genomic variations associated with mortality rate of COVID-19, J Hum Genet, doi:10.1038/s10038-020-0808-9
Tsang, Chan, Cho, An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies, Expert Rev Anti Infect Ther, doi:10.1080/14787210.2021.1863146
Uk, Diagnosis, None
Walley, Mantgani, The UK general practice research database, Lancet, doi:10.1016/S0140-6736(97)04248-7
Williamson, Walker, Bhaskaran, Factors associated with COVID-19-related death using OpenSAFELY, Nature, doi:10.1038/s41586-020-2521-4
Wolf, Dedman, Campbell, Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum, Int J Epidemiol, doi:10.1093/ije/dyz034
Zaim, Chong, Sankaranarayanan, COVID-19 and multiorgan response, Curr Probl Cardiol, doi:10.1016/j.cpcardiol.2020.100618
{ 'indexed': { 'date-parts': [[2023, 11, 23]], 'date-time': '2023-11-23T00:32:35Z', 'timestamp': 1700699555895}, 'reference-count': 56, 'publisher': 'BMJ', 'issue': '11', 'license': [ { 'start': { 'date-parts': [[2023, 11, 22]], 'date-time': '2023-11-22T00:00:00Z', 'timestamp': 1700611200000}, 'content-version': 'unspecified', 'delay-in-days': 21, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'funder': [ { 'DOI': '10.13039/100004325', 'name': 'AstraZeneca', 'doi-asserted-by': 'publisher', 'award': ['N/A']}], 'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 11]]}, 'abstract': '<jats:sec><jats:title>Objectives</jats:title><jats:p>Determine the prevaccination healthcare ' 'impact of COVID-19 in patients with systemic lupus erythematosus (SLE) in ' 'England.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>Retrospective ' 'cohort study of adult patients with SLE from 1 May to 31 October ' '2020.</jats:p></jats:sec><jats:sec><jats:title>Setting</jats:title><jats:p>Clinical Practice ' 'Research Datalink (CPRD) Aurum and Hospital Episode Statistics (HES) databases from general ' 'practitioners across England combining primary care and other health-related ' 'data.</jats:p></jats:sec><jats:sec><jats:title>Participants</jats:title><jats:p>Overall, 6145 ' 'adults with confirmed SLE diagnosis ≥1\u2009year prior to 1 May 2020 were included. Most ' 'patients were women (91.0%), white (67.1%), and diagnosed with SLE at age &lt;50 (70.8%). ' 'Patients were excluded if they had a COVID-19 diagnosis before 1 May ' '2020.</jats:p></jats:sec><jats:sec><jats:title>Primary and secondary outcome ' 'measures</jats:title><jats:p>Demographics and clinical characteristics were compared. ' 'COVID-19 severity was determined by patient care required and procedure/diagnosis codes. ' 'COVID-19 cumulative incidence, hospitalisation rates, lengths of stay and mortality rates ' 'were determined and stratified by SLE and COVID-19 ' 'severity.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 6145 ' 'patients, 3927 had mild, 1288 moderate and 930 severe SLE at baseline. The majority of ' 'patients with moderate to severe SLE were on oral corticosteroids and antimalarial ' 'treatments. Overall, 54/6145 (0.88%) patients with SLE acquired and were diagnosed with ' 'COVID-19, with 45 classified as mild, 6 moderate and 3 severe COVID-19. Cumulative incidence ' 'was higher in patients with severe SLE (1.4%) compared with patients classified as mild ' '(0.8%) or moderate (0.8%). Ten COVID-19-specific hospital admissions occurred (n=6 moderate; ' 'n=4 severe). Regardless of COVID-19 status, hospital admission rates and length of stay ' 'increased with SLE severity. Of 54 patients with SLE diagnosed with COVID-19, 1 (1.9%) ' 'COVID-19-related death was recorded in a patient with both severe SLE and severe ' 'COVID-19.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>SLE ' 'severity did not appear to impact COVID-19 outcomes in this study. The COVID-19 pandemic is ' 'evolving and follow-up studies are needed to understand the relationship between COVID-19 and ' 'SLE.</jats:p></jats:sec>', 'DOI': '10.1136/bmjopen-2022-071072', 'type': 'journal-article', 'created': { 'date-parts': [[2023, 11, 22]], 'date-time': '2023-11-22T17:36:13Z', 'timestamp': 1700674573000}, 'page': 'e071072', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Impact of SARS-CoV-2 infection on patients with systemic lupus erythematosus in England prior to ' 'vaccination: a retrospective observational cohort study', 'prefix': '10.1136', 'volume': '13', 'author': [ {'given': 'Adrian Paul J', 'family': 'Rabe', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2266-5938', 'authenticated-orcid': False, 'given': 'Wei Jie', 'family': 'Loke', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rubana N', 'family': 'Kalyani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Raj', 'family': 'Tummala', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Heide A', 'family': 'Stirnadel-Farrant', 'sequence': 'additional', 'affiliation': []}, {'given': 'John', 'family': 'Were', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kevin L', 'family': 'Winthrop', 'sequence': 'additional', 'affiliation': []}], 'member': '239', 'published-online': {'date-parts': [[2023, 11, 22]]}, 'reference': [ { 'key': '2023112209351676000_13.11.e071072.1', 'unstructured': 'World Health Organization . WHO Coronavirus (COVID-19) Dashboard 2022. ' 'Available: https://covid19.who.int/ [Accessed 9 Dec 2022].'}, { 'key': '2023112209351676000_13.11.e071072.2', 'doi-asserted-by': 'publisher', 'DOI': '10.3345/cep.2020.00493'}, { 'key': '2023112209351676000_13.11.e071072.3', 'doi-asserted-by': 'publisher', 'DOI': '10.4269/ajtmh.20-1496'}, { 'key': '2023112209351676000_13.11.e071072.4', 'doi-asserted-by': 'crossref', 'first-page': '1075', 'DOI': '10.1038/s10038-020-0808-9', 'article-title': 'SARS-CoV-2 genomic variations associated with mortality rate of ' 'COVID-19', 'volume': '65', 'author': 'Toyoshima', 'year': '2020', 'journal-title': 'J Hum Genet'}, { 'key': '2023112209351676000_13.11.e071072.5', 'doi-asserted-by': 'crossref', 'first-page': '1442', 'DOI': '10.1016/j.jaip.2021.01.012', 'article-title': 'Why do some people develop serious COVID-19 disease after infection, ' 'while others only exhibit mild symptoms?', 'volume': '9', 'author': 'Ballow', 'year': '2021', 'journal-title': 'J Allergy Clin Immunol Pract'}, { 'key': '2023112209351676000_13.11.e071072.6', 'doi-asserted-by': 'crossref', 'unstructured': 'Castro MC , Gurzenda S , Macário EM , et al . Characteristics, outcomes ' 'and risk factors for mortality of 522 167 patients hospitalised with ' 'COVID-19 in Brazil: a retrospective cohort study. BMJ Open ' '2021;11:e049089. doi:10.1136/bmjopen-2021-049089', 'DOI': '10.1136/bmjopen-2021-049089'}, { 'key': '2023112209351676000_13.11.e071072.7', 'doi-asserted-by': 'crossref', 'first-page': '877', 'DOI': '10.1080/14787210.2021.1863146', 'article-title': 'An update on COVID-19 pandemic: the epidemiology, pathogenesis, ' 'prevention and treatment strategies', 'volume': '19', 'author': 'Tsang', 'year': '2021', 'journal-title': 'Expert Rev Anti Infect Ther'}, { 'key': '2023112209351676000_13.11.e071072.8', 'doi-asserted-by': 'crossref', 'first-page': '1284', 'DOI': '10.1016/j.cell.2020.07.012', 'article-title': 'The impact of mutations in SARS-CoV-2 spike on viral infectivity and ' 'antigenicity', 'volume': '182', 'author': 'Li', 'year': '2020', 'journal-title': 'Cell'}, { 'key': '2023112209351676000_13.11.e071072.9', 'unstructured': 'Centers for Disease Control and Prevention . Symptoms of COVID-19 2022. ' 'Available: ' 'https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html#print ' '[Accessed 9 Dec 2022].'}, { 'key': '2023112209351676000_13.11.e071072.10', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/all.14364'}, { 'key': '2023112209351676000_13.11.e071072.11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cpcardiol.2020.100618'}, { 'key': '2023112209351676000_13.11.e071072.12', 'doi-asserted-by': 'crossref', 'unstructured': 'Jordan RE , Adab P , Cheng KK . Covid-19: risk factors for severe ' 'disease and death. BMJ 2020;368:m1198. doi:10.1136/bmj.m1198', 'DOI': '10.1136/bmj.m1198'}, { 'key': '2023112209351676000_13.11.e071072.13', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2019-215089'}, { 'key': '2023112209351676000_13.11.e071072.14', 'doi-asserted-by': 'crossref', 'unstructured': 'Katsuyama T , Tsokos GC , Moulton VR . Aberrant T cell signaling and ' 'subsets in systemic lupus erythematosus. Front Immunol 2018;9:1088. ' 'doi:10.3389/fimmu.2018.01088', 'DOI': '10.3389/fimmu.2018.01088'}, { 'key': '2023112209351676000_13.11.e071072.15', 'doi-asserted-by': 'crossref', 'first-page': '373', 'DOI': '10.1016/j.it.2017.02.001', 'article-title': 'Expanding the B cell-centric view of systemic lupus erythematosus', 'volume': '38', 'author': 'Morawski', 'year': '2017', 'journal-title': 'Trends Immunol'}, { 'key': '2023112209351676000_13.11.e071072.16', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nm.2752'}, { 'key': '2023112209351676000_13.11.e071072.17', 'doi-asserted-by': 'crossref', 'first-page': '252', 'DOI': '10.1002/acr.22938', 'article-title': 'Disease outcomes in glucocorticosteroid-naive patients with systemic ' 'lupus erythematosus', 'volume': '69', 'author': 'Sheane', 'year': '2017', 'journal-title': 'Arthritis Care Res (Hoboken)'}, { 'key': '2023112209351676000_13.11.e071072.18', 'doi-asserted-by': 'crossref', 'unstructured': 'Al Sawah S , Zhang X , Zhu B , et al . Effect of corticosteroid use by ' 'dose on the risk of developing organ damage over time in systemic lupus ' 'erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med 2015;2:e000066. ' 'doi:10.1136/lupus-2014-000066', 'DOI': '10.1136/lupus-2014-000066'}, { 'key': '2023112209351676000_13.11.e071072.19', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2013-205171'}, { 'key': '2023112209351676000_13.11.e071072.20', 'unstructured': 'LUPUS UK . Lupus & Coronavirus (COVID-19). Available: ' 'https://www.lupusuk.org.uk/coronavirus/#amiatrisk [Accessed 17 Mar ' '2023].'}, { 'key': '2023112209351676000_13.11.e071072.21', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.semarthrit.2020.06.012'}, { 'key': '2023112209351676000_13.11.e071072.22', 'doi-asserted-by': 'crossref', 'first-page': '13', 'DOI': '10.1016/j.trsl.2020.12.007', 'article-title': 'COVID-19 in patients with systemic lupus erythematosus: lessons learned ' 'from the inflammatory disease', 'volume': '232', 'author': 'Fernandez-Ruiz', 'year': '2021', 'journal-title': 'Transl Res'}, { 'key': '2023112209351676000_13.11.e071072.23', 'doi-asserted-by': 'crossref', 'first-page': '2893', 'DOI': '10.1007/s10067-022-06227-7', 'article-title': 'Systemic lupus erythematosus in the light of the COVID-19 pandemic: ' 'infection, vaccination, and impact on disease management', 'volume': '41', 'author': 'Mehta', 'year': '2022', 'journal-title': 'Clin Rheumatol'}, { 'key': '2023112209351676000_13.11.e071072.24', 'unstructured': 'Department of Health &amp; Social Care ;. Coronavirus (COVID-19) Scaling ' 'up our testing programmes. 2020. Available: ' 'https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/878121/coronavirus-covid-19-testing-strategy.pdf ' '[Accessed 24 May 2020].'}, { 'key': '2023112209351676000_13.11.e071072.25', 'doi-asserted-by': 'crossref', 'unstructured': 'Majeed A , Pollock K , Hodes S , et al . Implementation of COVID-19 ' 'vaccination in the United Kingdom. BMJ 2022:e070344. ' 'doi:10.1136/bmj-2022-070344', 'DOI': '10.1136/bmj-2022-070344'}, { 'key': '2023112209351676000_13.11.e071072.26', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ije/dyz034'}, { 'key': '2023112209351676000_13.11.e071072.27', 'unstructured': 'Medicines & Healthcare Products Regulatory Agency NIHR . Clinical ' 'Practice Research Datalink. 2022. Available: https://cprd.com/'}, { 'key': '2023112209351676000_13.11.e071072.28', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/pds.4747'}, { 'key': '2023112209351676000_13.11.e071072.29', 'doi-asserted-by': 'crossref', 'unstructured': 'Harshfield A , Abel GA , Barclay S , et al . Do GPs accurately record ' 'date of death? A UK observational analysis. BMJ Support Palliat Care ' '2020;10:e24. doi:10.1136/bmjspcare-2018-001514', 'DOI': '10.1136/bmjspcare-2018-001514'}, { 'key': '2023112209351676000_13.11.e071072.30', 'doi-asserted-by': 'publisher', 'DOI': '10.3111/13696998.2013.778270'}, { 'key': '2023112209351676000_13.11.e071072.31', 'doi-asserted-by': 'crossref', 'unstructured': 'Langham J , Barut V , Samnaliev M , et al . Disease severity, flares and ' 'treatment patterns in adults with systemic lupus erythematosus in the ' 'UK: a real-world observational retrospective cohort analysis. Rheumatol ' 'Adv Pract 2021;5:rkab061. doi:10.1093/rap/rkab061', 'DOI': '10.1093/rap/rkab061'}, { 'key': '2023112209351676000_13.11.e071072.32', 'unstructured': 'Office of National Statistics . England population mid-year estimate, ' 'population estimates. 2021. Available: ' 'https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates ' '[Accessed 24 May 2022].'}, { 'key': '2023112209351676000_13.11.e071072.33', 'unstructured': 'UK Health Security Agency . Coronavirus (COVID-19) in the UK. 2022. ' 'Available: ' 'https://coronavirus.data.gov.uk/details/cases?areaType=nation&areaName=England ' '[Accessed 10 Apr 2022].'}, { 'key': '2023112209351676000_13.11.e071072.34', 'unstructured': 'GOV.UK . Coronavirus (COVID-19): guidance. Available: ' 'https://www.gov.uk/government/collections/coronavirus-covid-19-list-of-guidance#full-publication-update-history ' '[Accessed 22 Mar 2023].'}, { 'key': '2023112209351676000_13.11.e071072.35', 'doi-asserted-by': 'crossref', 'unstructured': 'Martindale A-M , Pilbeam C , Mableson H , et al . Perspectives on ' 'COVID-19 testing policies and practices: a qualitative study with ' 'scientific advisors and NHS health care workers in England. BMC Public ' 'Health 2021;21:1216. doi:10.1186/s12889-021-11285-8', 'DOI': '10.1186/s12889-021-11285-8'}, { 'key': '2023112209351676000_13.11.e071072.36', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2521-4'}, { 'key': '2023112209351676000_13.11.e071072.37', 'doi-asserted-by': 'crossref', 'first-page': '152099', 'DOI': '10.1016/j.semarthrit.2022.152099', 'article-title': 'Predictors of infection requiring hospitalization in patients with ' 'systemic lupus erythematosus: a time-to-event analysis', 'volume': '57', 'author': 'Ko', 'year': '2022', 'journal-title': 'Semin Arthritis Rheum'}, { 'key': '2023112209351676000_13.11.e071072.38', 'unstructured': 'NHS . Shielded patient list. Available: ' 'https://digital.nhs.uk/coronavirus/shielded-patient-list#:~:text=Shielded%20Patient%20List%20(SPL)%20web,Digital%20on%2030%20June%202022 ' '[Accessed 17 Mar 2023].'}, { 'key': '2023112209351676000_13.11.e071072.39', 'unstructured': 'GOV.UK . Twice weekly rapid testing to be available to everyone in ' 'England. 2021. Available: ' 'https://www.gov.uk/government/news/twice-weekly-rapid-testing-to-be-available-to-everyone-in-england#:~:text=Everyone%20in%20England%20will%20be,April%2C%20the%20government%20has%20announced.&text=universal%20testing%20offer-,Everyone%20in%20England%20will%20be%20able%20to%20access%20free%2C%20regular,April%2C%20the%20government%20has%20announced ' '[Accessed 6 Apr 2023].'}, { 'key': '2023112209351676000_13.11.e071072.40', 'unstructured': 'NHS . Healthcare associated COVID-19 infections – further action. June ' '2020. Available: ' 'https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/06/Healthcare-associated-COVID-19-infections--further-action-24-June-2020.pdf ' '[Accessed 6 Apr 2020].'}, { 'key': '2023112209351676000_13.11.e071072.41', 'doi-asserted-by': 'publisher', 'DOI': '10.3399/BJGP.2020.0948'}, { 'key': '2023112209351676000_13.11.e071072.42', 'doi-asserted-by': 'crossref', 'first-page': '2499', 'DOI': '10.1007/s10067-021-05601-1', 'article-title': 'Impact of COVID-19 on rheumatology practice in the UK-a pan-regional ' 'rheumatology survey', 'volume': '40', 'author': 'Nune', 'year': '2021', 'journal-title': 'Clin Rheumatol'}, { 'key': '2023112209351676000_13.11.e071072.43', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2014-206334'}, { 'key': '2023112209351676000_13.11.e071072.44', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(97)04248-7'}, { 'key': '2023112209351676000_13.11.e071072.45', 'unstructured': 'Medicines & Healthcare Products Regulatory Agency CPRD . CPRD Aurum. ' '2022. Available: https://cprd.com/cprd-aurum-may-2022-dataset [Accessed ' '4 Apr 2023].'}, { 'key': '2023112209351676000_13.11.e071072.46', 'unstructured': 'LUPUS UK . Diagnosis. Available: https://www.lupusuk.org.uk/diagnosis/ ' '[Accessed 4 Apr 2023].'}, { 'key': '2023112209351676000_13.11.e071072.47', 'unstructured': 'NHS . National data opt-out. 2020. Available: ' 'https://digital.nhs.uk/data-and-information/publications/statistical/national-data-opt-out/september-2020 ' '[Accessed 4 Apr 2023].'}, { 'key': '2023112209351676000_13.11.e071072.48', 'doi-asserted-by': 'crossref', 'first-page': '257', 'DOI': '10.1007/s00296-019-04477-4', 'article-title': 'Comparison of an administrative algorithm for SLE disease severity to ' 'clinical SLE disease activity index scores', 'volume': '40', 'author': 'Speyer', 'year': '2020', 'journal-title': 'Rheumatol Int'}, { 'key': '2023112209351676000_13.11.e071072.49', 'unstructured': 'UK Health Security Agency . COVID-19: the green book, Chapter 14A. ' 'Coronavirus (COVID-19) vaccination information for public health ' 'professionals. 2022. Available: ' 'https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1057798/Greenbook-chapter-14a-28Feb22.pdf'}, { 'key': '2023112209351676000_13.11.e071072.50', 'unstructured': 'NHS . NHS offers COVID jab to clinically vulnerable and people 65 to 69. ' 'Available: ' 'https://www.england.nhs.uk/2021/02/nhs-offers-covid-jab-to-clinically-vulnerable-and-people-65-to-69/ ' '[Accessed 24 May 2022].'}, { 'key': '2023112209351676000_13.11.e071072.51', 'unstructured': 'Public Health England . Impact of COVID-19 vaccines on mortality in ' 'England: December 2020 to February 2021. In: Public Health England ' 'Report. 2021. Available: ' 'https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972592/COVID-19_vaccine_impact_on_mortality_240321.pdf'}, { 'key': '2023112209351676000_13.11.e071072.52', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/S41579-021-00573-0'}, { 'key': '2023112209351676000_13.11.e071072.53', 'doi-asserted-by': 'publisher', 'DOI': '10.3349/ymj.2021.62.11.961'}, { 'key': '2023112209351676000_13.11.e071072.54', 'doi-asserted-by': 'crossref', 'first-page': 'e613', 'DOI': '10.1016/S2665-9913(21)00221-6', 'article-title': 'Tolerance of COVID-19 vaccination in patients with systemic lupus ' 'erythematosus: the international VACOLUP study', 'volume': '3', 'author': 'Felten', 'year': '2021', 'journal-title': 'Lancet Rheumatol'}, { 'key': '2023112209351676000_13.11.e071072.55', 'doi-asserted-by': 'crossref', 'first-page': 'e582', 'DOI': '10.1016/S2665-9913(22)00190-4', 'article-title': 'Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity ' 'following initial COVID-19 vaccination series and additional dose in ' 'patients with SLE in New York City', 'volume': '4', 'author': 'Saxena', 'year': '2022', 'journal-title': 'Lancet Rheumatol'}, { 'key': '2023112209351676000_13.11.e071072.56', 'unstructured': 'Clinical Practice Research Datalink . CORYLUS UK: A retrospective ' 'observational cohort study of the impact of COVID-19 on systemic lupus ' 'erythematosus patients in England using data from linked primary and ' 'secondary care databases. 2021. Available: ' 'https://cprd.com/protocol/corylus-uk-retrospective-observational-cohort-study-impact-covid-19-systemic-lupus ' '[Accessed 9 Dec 2022].'}], 'container-title': 'BMJ Open', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/bmjopen-2022-071072', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 11, 22]], 'date-time': '2023-11-22T17:36:30Z', 'timestamp': 1700674590000}, 'score': 1, 'resource': {'primary': {'URL': 'https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2022-071072'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 11]]}, 'references-count': 56, 'journal-issue': { 'issue': '11', 'published-online': {'date-parts': [[2023, 11, 22]]}, 'published-print': {'date-parts': [[2023, 11]]}}, 'alternative-id': ['10.1136/bmjopen-2022-071072'], 'URL': 'http://dx.doi.org/10.1136/bmjopen-2022-071072', 'relation': {}, 'ISSN': ['2044-6055', '2044-6055'], 'subject': ['General Medicine'], 'container-title-short': 'BMJ Open', 'published': {'date-parts': [[2023, 11]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit